Delisting risk
Werewolf Therapeutics
Develops conditionally activated cytokine and T-cell-engager therapies for cancer.
$0.9251
After-hours close−0.02 (−1.93%)
At close$0.9433(−2.83%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.22 | — | — |
| Jul 2026 | −$0.28 | $0.08 | +128.6% |
| May 2026 | −$0.32 | −$0.28 | +12.5% |
| Mar 2026 | −$0.34 | −$0.20 | +41.2% |
| Nov 2025 | −$0.39 | −$0.36 | +7.7% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Jun 2021 | |||
| Apr 2021 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | −$0.22 | — | — | $18.3M | — | — |
| Jul 31, 2026 | −$0.28 | $0.08 | +128.6% | $21.0M | $21.0M | 0.0% |
| May 7, 2026 | −$0.32 | −$0.28 | +12.5% | — | — | — |
| Mar 27, 2026 | −$0.34 | −$0.20 | +41.2% | $300.0K | — | — |
| Nov 4, 2025 | −$0.39 | −$0.36 | +7.7% | — | — | — |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Aug 14, 2025 | ||||||
| May 8, 2025 | ||||||
| Mar 11, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 3, 2024 | ||||||
| Mar 7, 2024 | ||||||
| Nov 14, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 23, 2023 | ||||||
| Nov 10, 2022 | ||||||
| Aug 11, 2022 | ||||||
| May 10, 2022 | ||||||
| Mar 24, 2022 | ||||||
| Nov 10, 2021 | ||||||
| Aug 12, 2021 | ||||||
| Jun 10, 2021 | ||||||
| Apr 30, 2021 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||